<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639363</url>
  </required_header>
  <id_info>
    <org_study_id>Duclorexint</org_study_id>
    <nct_id>NCT03639363</nct_id>
  </id_info>
  <brief_title>4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings</brief_title>
  <acronym>Duclorexint</acronym>
  <official_title>Study on the Effect of the Universal Decontamination With Daily Bathing With 4% Chlorhexidine Gluconate on the Incidence of Hospital Acquired Infections in Intensive Care Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Toscana Gabriele Monasterio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the utility of 4% chlorhexidine gluconate (CHG) daily bathing to reduce
      hospital acquired infections in patients admitted to intensive care units. One group will be
      daily bathed with 4% CHG and the other group with standard soap.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2015</start_date>
  <completion_date type="Actual">May 2, 2016</completion_date>
  <primary_completion_date type="Actual">April 28, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hospital acquired infections incidence</measure>
    <time_frame>infections occured 48 hours after admission to ICU/PC-ICU</time_frame>
    <description>cumulative incidence of bloodstream infections (BSI), central line-associates BSI (CLABSI), urinary tract infections (UTI), catheter-associated UTI (CAUTI) and ventilator-associated pneumonias (VAP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-associated pnemonias (VAP) incidence</measure>
    <time_frame>infections occured 48 hours after admission to ICU/PC-ICU</time_frame>
    <description>VAP incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bloodstream infections (BSI) incidence</measure>
    <time_frame>infections occured 48 hours after admission to ICU/PC-ICU</time_frame>
    <description>BSI incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central-line associated BSI (CLABSI) incidence</measure>
    <time_frame>infections occured 48 hours after admission to ICU/PC-ICU</time_frame>
    <description>CLABSI incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary tract infections (UTI) incidence</measure>
    <time_frame>infections occured 48 hours after admission to ICU/PC-ICU</time_frame>
    <description>UTI incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catheter associated UTI (CAUTI) incidence</measure>
    <time_frame>infections occured 48 hours after admission to ICU/PC-ICU</time_frame>
    <description>CAUTI incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4% CHG daily bathing safety</measure>
    <time_frame>at discharge, approximately up to 10 days</time_frame>
    <description>overall mortality in the treatment and control arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4% CHG daily bathing-related adverse events</measure>
    <time_frame>at discharge, approximately up to 10 days</time_frame>
    <description>4% CHG daily bathing-related adverse events in the treatment arm compared to standard soap-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time till infection</measure>
    <time_frame>at discharge, approximately up to 10 days</time_frame>
    <description>time between admission to ICU/PC-ICU and infection occurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Hospital Infection</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily bathing with standard soap</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4% chlorhexidine gluconate soap-like solution</intervention_name>
    <description>humidify the whole body surface with the exception of the face using water-impregnated washcloths
use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG
wait for at least 30 seconds
rinse using water-impregnated washcloths</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard soap</intervention_name>
    <description>humidify the whole body surface with the exception of the face using water-impregnated washcloths
use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face
wait for at least 30 seconds
rinse using water-impregnated washcloths</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  admission to the intensive care unit (ICU) or to the post-operative cardiosurgical ICU
             (PC-ICU)

          -  ICU/PC-ICU stay for at least 1 night

        Exclusion Criteria:

          -  known allergy to chlorhexidine

          -  burns, toxic epidermal necrolysis or Stevens-Johnson syndrome as admission diagnosis

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>franco baldelli, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Infectious Diseases Clinical, University Hospital of Perugia, Perugia, Italy</affiliation>
  </overall_official>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>August 17, 2018</last_update_submitted>
  <last_update_submitted_qc>August 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Carlo Pallotto</investigator_full_name>
    <investigator_title>Medical Doctor, Principal investigator</investigator_title>
  </responsible_party>
  <keyword>4% chlorhexidine gluconate</keyword>
  <keyword>infection control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03639363/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

